Small Pharma Inc logo

DMT - Small Pharma Inc News Story

C$0.385 0.0  0.0%

Last Trade - 23/09/21

Sector
Healthcare
Size
Market Cap £0.22
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 2705

Small Pharma Engages LifeSci Advisors as Investor Relations Agency

Tue 22nd June, 2021 1:00pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210622:nGNX4G1CM2&default-theme=true


LONDON, June 22, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (the
“Company” or “Small Pharma”) is pleased to announce that it has
retained LifeSci Advisors, LLC (“LSA”) to provide investor relations
services.

Peter Rands, CEO of Small Pharma, said: “In line with our go-public
strategy, Small Pharma is now focused on driving greater understanding of the
benefits of psychedelic-assisted therapies and their potential to change the
landscape of mental health treatment. Building on our already strong and
supportive shareholder base will be key to enabling the Company to deliver its
portfolio of psychedelic-assisted therapies for depression, a serious
condition that afflicts more than 300 million people worldwide(1). With
topline results of the Phase I/IIa clinical trial of our lead product
anticipated in the first half of 2022, we look forward to creating a
comprehensive investor interface to aid access and knowledge of our mission
here at Small Pharma, in North America, Europe and beyond.”

LSA has agreed to comply with all applicable securities laws and the policies
of the TSX Venture Exchange (the “TSXV”) in providing the services to the
Company. LSA will receive a monthly fee of U.S.$19,500 plus applicable taxes.
The agreement between the Company and LSA dated June 20, 2021 is for an
initial term of six (6) months and shall be automatically renewed for
successive six (6) month periods (collectively, the “Term”) unless either
the Company or LSA provides written notice of termination at least 30 days
prior to the end of the Term. No stock options or other compensation are being
granted in connection with the engagement.

LSA, with over 250 employees and a local presence that spans, New York,
Chicago, Boston, London, Geneva, Paris, and Tel-Aviv, provides life science
companies comprehensive solutions to communications and investor outreach.
Taking a partner approach, LSA increases client visibility within the
investment community and educates investors on opportunities with its clients
through non-deal roadshow planning and execution, KOL Events/R&D Days, and
corporate communications.

About Small Pharma

Small Pharma is a neuropharmaceutical company specialised in IP led
development of novel treatments for mental health conditions, with a focus on
depression. Small Pharma initiated a clinical program into
N,N-dimethyltryptamine (“DMT”) assisted therapy in February 2021. This
program includes a Phase I/IIa trial on their lead candidate alongside
development of a robust pipeline of proprietary preclinical assets.

For further information contact: 

Small Pharma Inc.

Peter Rands 
Chief Executive Officer
Email: ir@smallpharma.co.uk
Tel: +44 (0)2071 129118

INVESTOR RELATIONS CONTACT
Eric Ribner
LifeSci Advisors
Email: eric@lifesciadvisors.com

Cautionary Note

Small Pharma makes no medical, treatment or health benefit claims about its
proposed products. The Medicines and Healthcare products Regulatory Agency
(“MHRA”) or other similar regulatory authorities have not evaluated claims
regarding DMT-assisted therapies and other next generation psychoactive
compounds. The efficacy of such therapies have not been confirmed by
MHRA-approved research. There is no assurance that such DMT-assisted therapies
and other psychoactive compounds can diagnose, treat, cure or prevent any
disease or condition. Vigorous scientific research and clinical trials are
needed. Any references to quality, consistency, efficacy and safety of
potential therapies do not imply that Small Pharma verified such in clinical
trials or that Small Pharma will complete such trials. If Small Pharma cannot
obtain the approvals or research necessary to commercialize its business, it
may have a material adverse effect on Small Pharma’s performance and
operations.

The TSXV has neither approved nor disapproved the contents of this news
release. Neither the TSXV nor its Regulation Services Provider (as that term
is defined in the policies of the TSXV) accepts responsibility for the
adequacy or accuracy of this release.

_________________________________
(1) STAR*D Trial:
https://www.nimh.nih.gov/funding/clinical-research/practical/stard/allmedicationlevels.shtml



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.